Pharmacological targeting of CDK9 in cardiac hypertrophy. - Wikidata - wikimedia - TriplyDB

Pharmacological targeting of CDK9 in cardiac hypertrophy.

Pharmacological targeting of CDK9 in cardiac hypertrophy.

http://www.wikidata.org/entity/Q37598171

about

7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508 A Pipeline for Drug Target Identification and Validation RelA Ser276 phosphorylation-coupled Lys310 acetylation controls transcriptional elongation of inflammatory cytokines in respiratory syncytial virus infection.Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study.CDK9 and its repressor LARP7 modulate cardiomyocyte proliferation and response to injury in the zebrafish heart Complex effects of flavopiridol on the expression of primary response genes Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.Cyclin K goes with Cdk12 and Cdk13 Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.

P2860

Q24634280-051464DA-7512-4114-BFB5-1363ED9E65A1 Q27676963-D8AD97CA-98E4-4F50-A25C-528DFF53E978 Q33793854-544A124F-D5FD-4DF1-B632-CF9E80204380 Q35531231-14AABE27-3FAE-4C44-AE10-AAFA1FF95476 Q35536739-99362C8C-8DA1-45DE-A942-507478F2D089 Q35834044-5034403C-EA83-4B8B-99F2-9A412280415F Q35920526-369F77BB-E58B-42FD-B1E5-2B1628091958 Q36738991-BE390F9D-9285-4B53-A8BC-ED4AE6086CFB Q38003504-AAF7BC24-3165-4633-99AB-C797B7111F05 Q38008733-4027303F-8A38-4776-A2C1-1C301896663B Q41457054-D43917DC-8B58-4A9E-AB90-21EE2AC9C7E9

P2860

Pharmacological targeting of CDK9 in cardiac hypertrophy.

http://www.wikidata.org/entity/Q37598171

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@en

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@nl

type

label

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@en

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@nl

prefLabel

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@en

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@nl

P1433

Q37598171-C8CE8978-75FC-45A4-963D-56B3E2B28393

P1476

Q37598171-A175BF27-3F3D-4FDD-ADAF-6850E890029D

P2093

Q37598171-32436275-2A3A-4BDB-8220-0A57C30FD117

Q37598171-62A3C8EA-3050-4C9D-81C2-046FE7111356

Q37598171-7A0397A4-3292-4B8C-A38E-654C206A5227

Q37598171-953E99FC-9691-4A2A-A664-94D031D52625

P2860

Q37598171-3BE2D5A1-22EE-434D-A6E0-2D30B50F6B67

Q37598171-673BE198-20FB-4CCC-AFFE-E4B30588D2C9

Q37598171-79D72D51-C907-4FB6-A7E0-92A69FC389C4

Q37598171-7FB00E0D-909B-4293-AFA4-7FA8AAB6E7A3

Q37598171-8D167D42-DB83-4B3C-AF27-96FF6E692EBA

Q37598171-AE22890F-A6FA-481C-8CF0-7B7E5D49E729

Q37598171-D823E6BD-6441-4C3B-80D3-1613F0F66363

P304

Q37598171-150B2D34-71C4-4DB7-8605-E7BF5F69BA02

P31

Q37598171-515CC6C7-7408-4989-9839-3939C6CE9D2D

P356

Q37598171-580BD1F8-627F-4D8E-A925-570BF484CE2D

P433

Q37598171-9732BFF9-4721-44A2-A568-C0DE30C2B98D

P478

Q37598171-091DF430-9CC7-4AB4-A5C1-FE9136362888

P577

Q37598171-9A9751B3-C6A8-44DE-AE9D-757E3EFB0136

P5875

Q37598171-C9A4B84C-1730-4EE2-BBB6-5B7D0EF4D68F

P698

Q37598171-935F4CE7-DDB5-4133-958A-BC4FDE32CD88

P921

Q37598171-2F7CD99C-1B12-4BB1-BFF2-E3C7C058F97E

P356

P1433

Medicinal Research Reviews

P1476

Pharmacological targeting of CDK9 in cardiac hypertrophy.

@en

P2093

Ivo Chamrád

http://www.w3.org/2001/XMLSchema#string

Jirí Kohoutek

http://www.w3.org/2001/XMLSchema#string

Radek Jorda

http://www.w3.org/2001/XMLSchema#string

Vladimír Krystof

http://www.w3.org/2001/XMLSchema#string

P2860

Protein kinase cascades in the regulation of cardiac hypertrophy

Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy.

Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.

B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

P304

646-666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MED.20172

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26815230

http://www.w3.org/2001/XMLSchema#string

P698

19757441

http://www.w3.org/2001/XMLSchema#string

P921